ReviewCardiovascular therapeutics2019
Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More?
Review in Cardiovascular therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Influence of Sex and Cardiometabolic Risk Factors on the High-Sensitivity Cardiac Troponins at the Concentrations Used as the Thresholds for Cardiovascular Risk Stratification in a Presumably Healthy Polish Population.Journal of clinical medicine · 2024Article
- Review
- Evaluation of Age and Sex Differences in Contemporary versus High-Sensitivity Troponin I Measurement in Hospitalized Patients.Journal of clinical medicine · 2024Article
- Sex-disparities in chest pain workup: a retrospective cohort review of a university based clinical decision pathway.BMC cardiovascular disorders · 2023Article
- Measurement of Cardiac-Specific Biomarkers in the Emergency Department: New Insight in Risk Evaluation.International journal of molecular sciences · 2023Review
- Sex Differences in the Diagnosis, Management, and Outcomes of Suspected Non-ST-Elevation Acute Coronary Syndromes Meeting Rapid Rule-Out Criteria.Journal of clinical medicine · 2023Article
- Biomolecules and Cardiovascular Diseases in Women.Biomolecules · 2022Article
- High-sensitivity cardiac troponin I after coronary artery bypass grafting for post-operative decision-making.European heart journal · 2022Article
- Sex-based differences in remote monitoring of biometric, psychometric and biomarker indices in stable ischemic heart disease.Biology of sex differences · 2022Article
- Biology of Cardiac Troponins: Emphasis on Metabolism.Biology · 2022Review
- Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications.Circulation research · 2022Review
- Metabolic Pathway of Cardiospecific Troponins: From Fundamental Aspects to Diagnostic Role (Comprehensive Review).Frontiers in molecular biosciences · 2022Review
- High-Sensitivity Troponin: A Review on Characteristics, Assessment, and Clinical Implications.Disease markers · 2022Review
- The Importance of Cardiac Troponin Metabolism in the Laboratory Diagnosis of Myocardial Infarction (Comprehensive Review).BioMed research international · 2022Review
- Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients.Frontiers in medicine · 2022Article
- Retrospective validation of a machine learning clinical decision support tool for myocardial infarction risk stratification.Healthcare technology letters · 2021Article
- Inconsistent Findings of Cardiac Troponin T and I in Clinical Routine Diagnostics: Factors of Influence.Journal of clinical medicine · 2021Article
- Crucial considerations: Sex differences in the epidemiology, diagnosis, treatment, and outcomes of acute pulmonary embolism in non-pregnant adult patients.Journal of the American College of Emergency Physicians open · 2021Review
- Cardiac Troponin Assays With Improved Analytical Quality: A Trade-Off Between Enhanced Diagnostic Performance and Reduced Long-Term Prognostic Value.Journal of the American Heart Association · 2020Observational
- Sex-related differences in contemporary biomarkers for heart failure: a review.European journal of heart failure · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of patients presenting to the Emergency Department with chest pain is continuously evolving. In the setting of acute coronary syndrome, the availability of high-sensitivity cardiac troponin assays (hs-cTn) has allowed for the development of algorithms aimed at rapidly assessing the risk of an ongoing myocardial infarction. However, concerns were raised about the massive application of such a simplified approach to heterogeneous real-world populations. As a result, there is a potential risk of underdiagnosis in several clusters of patients, including women, for whom a lower threshold for hs-cTn was suggested to be more appropriate. Implementation in clinical practice of sex-tailored cut-off values for hs-cTn represents a hot topic due to the need to reduce inequality and improve diagnostic performance in females. The aim of this review is to summarize current evidence on sex-specific cut-off values of hs-cTn and their application and usefulness in clinical practice. We also offer an extensive overview of thresholds reported in literature and of the mechanisms underlying such differences among sexes, suggesting possible explanations about debated issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.